SCHEMBL140549

SCHEMBL140549

COc1ccc2nc(Nc3cc(Cc4ccccc4)nc(NCCc4ccc(S(N)(=O)=O)cc4)n3)sc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.58
ITK Q08881 5/20 0.58
AURKB Q96GD4 5/20 0.58
CA1 P00915 8/20 0.51
CA2 P00918 8/20 0.51
CA12 O43570 4/20 0.51
CA7 P43166 1/20 0.51
BCHE P06276 2/20 0.50
ACHE P22303 2/20 0.50
EGFR P00533 1/20 0.46
INSR P06213 1/20 0.46
SRC P12931 1/20 0.46
TEC P42680 1/20 0.46
TXK P42681 1/20 0.46
BMX P51813 1/20 0.46
BTK Q06187 1/20 0.46
LRRK2 Q5S007 1/20 0.46
CAMKK2 Q96RR4 1/20 0.46
IRAK4 Q9NWZ3 1/20 0.46
CA9 Q16790 7/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140730 0.90 AURKB (0.58) LCKITKAURKBCA1CA2
SCHEMBL138536 0.90 AURKB (0.57) LCKITKAURKBCA1CA2
SCHEMBL140615 0.88 AURKB (0.47) LCKITKAURKBCA1CA2
SCHEMBL139728 0.88 AURKB (0.49) LCKITKAURKBCA1CA2
SCHEMBL136566 0.87 AURKB (0.56) LCKITKAURKBCA1CA2
SCHEMBL140042 0.83 AURKB (0.68) LCKITKAURKBBCHEACHE
SCHEMBL139699 0.79 CA1 (0.48) LCKITKAURKBCA1CA2
SCHEMBL139888 0.79 LCK (0.57) LCKITKAURKBCA1CA2
SCHEMBL141931 0.79 LCK (0.56) LCKITKAURKBEGFRINSR
SCHEMBL141009 0.79 AURKB (0.65) LCKITKAURKBBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.